SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

Better breathing with fast control at 15 minutes each time1,3

  • SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

  • Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (for example, discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an ICS

In patients taking SYMBICORT 160/4.5 (n=124) in Study 1, 79% of 2-hour postdose FEV1 improvement occurred at 15 minutes on day of randomization, 89% at week 2, and 90% at end of treatment.1-3

Sustained improvement in lung function was demonstrated in a 12-week efficacy and safety study.1,3

FAST CONTROL

SUSTAINED EFFECT

SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

Better breathing with fast control at 15 minutes each time1,3

  • SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

  • Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (for example, discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an ICS

In patients taking SYMBICORT 160/4.5 (n=124) in Study 1, 79% of 2-hour postdose FEV1 improvement occurred at 15 minutes on day of randomization, 89% at week 2, and 90% at end of treatment.1-3

Sustained improvement in lung function was demonstrated in a 12-week efficacy and safety study.1,3

FAST CONTROL

SUSTAINED EFFECT

Study Findings About SYMBICORT for Asthma

In a 12-week efficacy and safety study of patients with moderate to severe asthma:

SYMBICORT 160/4.5 significantly improved predose FEV1 (P<.05 vs budesonide, formoterol, and placebo) averaged over the course of the study, and also improved 12-hour average postdose FEV1 (P<.001 vs budesonide, formoterol, and placebo at week 2), coprimary endpoints1; 2-hour postdose FEV1 over 12 weeks was a secondary endpoint.3

ASTHMA PATIENT PROFILE

Learn more about patients who may be right for SYMBICORT.

SYMBICORT DOSAGE

Find helpful information you need to prescribe SYMBICORT for asthma.

FORMULARY FINDER

Find the formulary status of SYMBICORT in your area.

*Subject to eligibility rules; restrictions apply.